HPS Pharmacies wish to give notice that all presentations of irbesartan and irbesartan with hydrochlorothiazide are experiencing supply issues as summarised below:
|Product||ARTG||Expected Return Date|
|Avsartan 75mg||268780||Early June 2019|
|Avsartan 150mg||268774||Early June 2019|
|Avsartan 300 mg||268772||Early June 2019|
|Avsartan HCT 150/12.5||272655||Early June 2019|
|Avsartan HCT 300/12.5||272659||Early June 2019|
|Avsartan HCT 300/25||272662||Early June 2019|
This supply interruption follows the discontinuation of a number of generic brands of irbesartan and irbesartan with hydrochlorothiazide. This has resulted in an unexpected increase in demand for the remaining brands on the market. While wholesaler stocks have been affected, HPS Pharmacies has access to a limited supply of irbesartan and irbesartan with hydrochlorothiazide for the benefit of our clients.
Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact your pharmacist at HPS Pharmacies